ICMR cautious about Dexamethasone use in COVID-19 treatment


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ icmr-cautious-about-dexamethasone-use-covid19-treatment
Dexamethasone can bring down deaths to 20% in comparison to 25% while on standard care

Dexamethasone is being hailed as a breakthrough because the steroid has shown the first signs of reduced mortality in severely ill COVID-19 patients. A recovery trial within the UK, the biggest such trial within the world for therapies for coronavirus, has found that low doses of dexamethasone can save a COVID-19 patient on a ventilator. But India remains very cautious towards the attention the steroid has received in the world. One among the explanations is that the steroid still has got to undergo various scientific scrutinies.
The study data showed that the fatality rate in patients, who required ventilation and were being administered dexamethasone, fell from 41% to 28%. In intermediate patients, who required oxygen support only, the deaths were reduced by a fifth thanks to dexamethasone. Dexamethasone can bring down deaths to 20% in comparison to 25% while on standard care.
ICMR has taken clinical precision towards the utilization of dexamethasone as a wonder drug for the deadly virus.

A top ICMR official is reportedly quoted as saying, "Giving a steroid to hypertensive and diabetic patients is often challenging. it might be great if the evidence suggests that it's ready to contain a cytokine storm. Then the drug is going to be the most cost-effective alternative to currently studied monoclonal antibodies. it might be premature to discuss it before it's published."

The concern isn't wrong. At this moment, the information of the case histories of patients has not been presented. We don't know if the steroid was administered to patients who may have had severe co-morbidities like a thyroid disorder; stomach ulcers, colitis, or diverticulitis; depression, mental disease, or psychosis; liver disease (especially cirrhosis); high blood pressure; osteoporosis; a muscle disorder like myasthenia gravis; or disseminated sclerosis. India’s death figures have also hinted that the majority of people that died of COVID-19 had underlying co-morbidities.
Dr. Mande DG, CSIR reportedly said that until today, many doctors around the world and India probably would have already tried this out on patients who are critically ill.
"Dexamethasone should only be taken under medical supervision and is clearly just for critically ill patients, one shouldn't choose self-medication,” Dr. Mande was quoted as saying by a reputed news media.
In India, anti-inflammatory remdesivir has been sanctioned as a treatment of critical patients within the clinical protocols issued by the Union Health Ministry last week. The drug is patented by Gilead Science and is an intravenous drug utilized in hospital settings only.
There is no ambiguity that there is a distinct difference between remdesivir and dexamethasone, and their efficacies as possible therapies for coronavirus. “The difference between remdesivir and dexamethasone is that the previous reduce stay in hospitals from 14 days to 10-11 days as claimed during a clinical test, while dexamethasone’s claimed benefit is that it reduces the mortality in critically-ill COVID-19 patients,” Dr. Mande reportedly said.
Dr. Mande also stated that a variety of trials on a number of the anti-inflammatory molecules are underway in India. India is the biggest manufacturer of dexamethasone, which is out there as a tablet also as an injection. over 20 companies sell the drug and it's cheaply available across the market. Fortunately for the coronavirus patients, the drug is reasonable and costs but Rs 3 for a strip of 10 tables. the united kingdom has begun to stockpile this drug.

Tags : #Coronavirus #ICMR #Dexamethasone #Remdesivir #WonderDrug #India

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026